You just read:

Soligenix Announces $1.5 Million NCI SBIR Grant Award Supporting the Pivotal Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma

News provided by

Soligenix, Inc.

Sep 18, 2017, 06:00 ET